RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 1.15 Million USD | 1832.54% |
| 2021 | -66.69 Thousand USD | -111.15% |
| 2020 | 598.33 Thousand USD | 528.71% |
| 2019 | 95.16 Thousand USD | 152.14% |
| 2018 | -182.5 Thousand USD | -140.28% |
| 2017 | 453.14 Thousand USD | 965.55% |
| 2016 | 42.52 Thousand USD | -88.54% |
| 2015 | 371.22 Thousand USD | 233.52% |
| 2014 | -278.02 Thousand USD | -165.23% |
| 2013 | 426.23 Thousand USD | 218.82% |
| 2012 | 133.69 Thousand USD | 215.16% |
| 2011 | -116.09 Thousand USD | 96.94% |
| 2010 | -3.79 Million USD | 12.98% |
| 2009 | -4.35 Million USD | 22.98% |
| 2008 | -5.65 Million USD | -52.98% |
| 2007 | -3.69 Million USD | 71.68% |
| 2006 | -13.05 Million USD | -166.58% |
| 2005 | -4.89 Million USD | -70.34% |
| 2004 | -2.87 Million USD | -181.82% |
| 2003 | -1.01 Million USD | -115.01% |
| 2002 | -474.33 Thousand USD | -372.03% |
| 2001 | -100.49 Thousand USD | 70.04% |
| 2000 | -335.42 Thousand USD | -229.84% |
| 1999 | 258.33 Thousand USD | -33.65% |
| 1998 | 389.34 Thousand USD | 339.29% |
| 1997 | 88.63 Thousand USD | 157.66% |
| 1996 | -153.72 Thousand USD | 71.89% |
| 1995 | -546.79 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.39 Million USD | 20.56% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 551.48 Thousand USD | 92.7% |
| 2022 FY | 1.15 Million USD | 1832.54% |
| 2022 Q4 | 1.15 Million USD | 26.94% |
| 2022 Q1 | 286.19 Thousand USD | 529.14% |
| 2022 Q3 | 910.24 Thousand USD | 65.05% |
| 2021 Q3 | -406.89 Thousand USD | 54.88% |
| 2021 Q4 | -66.69 Thousand USD | 83.61% |
| 2021 FY | -66.69 Thousand USD | -111.15% |
| 2021 Q2 | -901.87 Thousand USD | -203.99% |
| 2021 Q1 | 867.26 Thousand USD | 44.95% |
| 2020 Q2 | 542.75 Thousand USD | 275.37% |
| 2020 Q1 | 144.59 Thousand USD | 51.93% |
| 2020 FY | 598.33 Thousand USD | 528.71% |
| 2020 Q4 | 598.33 Thousand USD | -26.03% |
| 2020 Q3 | 808.88 Thousand USD | 49.03% |
| 2019 FY | 95.16 Thousand USD | 152.14% |
| 2019 Q1 | -298.12 Thousand USD | -63.35% |
| 2019 Q2 | -487.01 Thousand USD | -63.36% |
| 2019 Q3 | -172.18 Thousand USD | 64.65% |
| 2019 Q4 | 95.16 Thousand USD | 155.27% |
| 2018 Q1 | -484.15 Thousand USD | -206.84% |
| 2018 FY | -182.5 Thousand USD | -140.28% |
| 2018 Q2 | -203.58 Thousand USD | 57.95% |
| 2018 Q3 | -344.6 Thousand USD | -69.27% |
| 2018 Q4 | -182.5 Thousand USD | 47.04% |
| 2017 FY | 453.14 Thousand USD | 965.55% |
| 2017 Q4 | 453.14 Thousand USD | -36.41% |
| 2017 Q3 | 712.66 Thousand USD | 13.16% |
| 2017 Q1 | 358.67 Thousand USD | 743.4% |
| 2017 Q2 | 629.77 Thousand USD | 75.58% |
| 2016 Q2 | -858.85 Thousand USD | -234.27% |
| 2016 Q1 | 639.64 Thousand USD | 72.31% |
| 2016 Q4 | 42.52 Thousand USD | 115.17% |
| 2016 FY | 42.52 Thousand USD | -88.54% |
| 2016 Q3 | -280.31 Thousand USD | 67.36% |
| 2015 FY | 371.22 Thousand USD | 233.52% |
| 2015 Q2 | 64.01 Thousand USD | 113.73% |
| 2015 Q1 | -466.19 Thousand USD | -67.68% |
| 2015 Q4 | 371.22 Thousand USD | 20474.7% |
| 2015 Q3 | -1822.00 USD | -102.85% |
| 2014 Q3 | -706.59 Thousand USD | -304.31% |
| 2014 FY | -278.02 Thousand USD | -165.23% |
| 2014 Q4 | -278.02 Thousand USD | 60.65% |
| 2014 Q2 | -174.76 Thousand USD | 79.04% |
| 2014 Q1 | -833.96 Thousand USD | -295.66% |
| 2013 Q3 | 224.28 Thousand USD | -22.0% |
| 2013 Q1 | 43.98 Thousand USD | -67.1% |
| 2013 FY | 426.23 Thousand USD | 218.82% |
| 2013 Q2 | 287.55 Thousand USD | 553.82% |
| 2013 Q4 | 426.23 Thousand USD | 90.04% |
| 2012 Q4 | 133.69 Thousand USD | 517.23% |
| 2012 FY | 133.69 Thousand USD | 215.16% |
| 2012 Q3 | -32.04 Thousand USD | -7.22% |
| 2012 Q1 | -135.51 Thousand USD | -16.73% |
| 2012 Q2 | -29.88 Thousand USD | 77.95% |
| 2011 Q3 | -524.45 Thousand USD | 77.06% |
| 2011 Q4 | -116.09 Thousand USD | 77.86% |
| 2011 FY | -116.09 Thousand USD | 96.94% |
| 2011 Q1 | -3.9 Million USD | -3.15% |
| 2011 Q2 | -2.28 Million USD | 41.53% |
| 2010 Q1 | -3.18 Million USD | 26.76% |
| 2010 Q4 | -3.79 Million USD | 23.83% |
| 2010 Q2 | -6.59 Million USD | -106.62% |
| 2010 Q3 | -4.97 Million USD | 24.51% |
| 2010 FY | -3.79 Million USD | 12.98% |
| 2009 Q3 | -1.1 Million USD | 61.43% |
| 2009 FY | -4.35 Million USD | 22.98% |
| 2009 Q4 | -4.35 Million USD | -292.81% |
| 2009 Q2 | -2.87 Million USD | 26.36% |
| 2009 Q1 | -3.9 Million USD | 30.96% |
| 2008 Q2 | -7.65 Million USD | 23.15% |
| 2008 Q1 | -9.95 Million USD | -169.39% |
| 2008 FY | -5.65 Million USD | -52.98% |
| 2008 Q4 | -5.65 Million USD | -4.98% |
| 2008 Q3 | -5.38 Million USD | 29.62% |
| 2007 Q4 | -3.69 Million USD | -100.74% |
| 2007 FY | -3.69 Million USD | 71.68% |
| 2007 Q2 | -3.52 Million USD | -126.37% |
| 2007 Q3 | -1.84 Million USD | 47.81% |
| 2007 Q1 | -1.55 Million USD | 88.06% |
| 2006 Q3 | -5.42 Million USD | 12.95% |
| 2006 Q4 | -13.05 Million USD | -140.69% |
| 2006 FY | -13.05 Million USD | -166.58% |
| 2006 Q1 | -9.81 Million USD | -100.38% |
| 2006 Q2 | -6.22 Million USD | 36.51% |
| 2005 Q3 | -4.12 Million USD | 19.58% |
| 2005 Q4 | -4.89 Million USD | -18.61% |
| 2005 Q2 | -5.13 Million USD | 17.52% |
| 2005 Q1 | -6.22 Million USD | -116.51% |
| 2005 FY | -4.89 Million USD | -70.34% |
| 2004 Q4 | -2.87 Million USD | -30.18% |
| 2004 FY | -2.87 Million USD | -181.82% |
| 2004 Q3 | -2.2 Million USD | -36.89% |
| 2004 Q2 | -1.61 Million USD | 26.29% |
| 2004 Q1 | -2.18 Million USD | -114.54% |
| 2003 Q3 | -1.39 Million USD | 28.0% |
| 2003 Q4 | -1.01 Million USD | 26.82% |
| 2003 Q1 | -301.05 Thousand USD | 36.53% |
| 2003 Q2 | -1.93 Million USD | -542.93% |
| 2003 FY | -1.01 Million USD | -115.01% |
| 2002 FY | -474.33 Thousand USD | -372.03% |
| 2002 Q4 | -474.33 Thousand USD | 40.1% |
| 2002 Q3 | -791.91 Thousand USD | 29.98% |
| 2002 Q2 | -1.13 Million USD | 31.15% |
| 2002 Q1 | -1.64 Million USD | -1534.83% |
| 2001 FY | -100.49 Thousand USD | 70.04% |
| 2001 Q4 | -100.49 Thousand USD | 48.31% |
| 2001 Q3 | -194.42 Thousand USD | 32.47% |
| 2001 Q2 | -287.9 Thousand USD | 30.92% |
| 2001 Q1 | -416.75 Thousand USD | -24.25% |
| 2000 Q2 | -443.86 Thousand USD | 18.16% |
| 2000 FY | -335.42 Thousand USD | -229.84% |
| 2000 Q1 | -542.35 Thousand USD | -309.94% |
| 2000 Q3 | -344.08 Thousand USD | 22.48% |
| 2000 Q4 | -335.42 Thousand USD | 2.52% |
| 1999 FY | 258.33 Thousand USD | -33.65% |
| 1999 Q4 | 258.33 Thousand USD | 0.0% |
| 1998 Q1 | 180 Thousand USD | 100.0% |
| 1998 FY | 389.34 Thousand USD | 339.29% |
| 1998 Q4 | 390 Thousand USD | 0.0% |
| 1998 Q2 | 270 Thousand USD | 50.0% |
| 1997 Q1 | -110 Thousand USD | 26.67% |
| 1997 Q3 | 40 Thousand USD | 500.0% |
| 1997 Q4 | 90 Thousand USD | 125.0% |
| 1997 Q2 | -10 Thousand USD | 90.91% |
| 1997 FY | 88.63 Thousand USD | 157.66% |
| 1996 Q3 | -120 Thousand USD | -200.0% |
| 1996 Q1 | -290 Thousand USD | 0.0% |
| 1996 Q2 | -40 Thousand USD | 86.21% |
| 1996 FY | -153.72 Thousand USD | 71.89% |
| 1996 Q4 | -150 Thousand USD | -25.0% |
| 1995 FY | -546.79 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 88300.687% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 79.544% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.3% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 562.875% |
| Rebus Holdings, Inc. | 305 Thousand USD | -278.829% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 118.327% |
| Qrons Inc. | 351.42 Thousand USD | -228.782% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -85.652% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.34% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 5761.647% |
| Skye Bioscience, Inc. | -5.72 Million USD | 120.195% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 92.67% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 71.942% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -187.528% |
| SQZ Biotechnologies Company | -36.23 Million USD | 103.188% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 48.47% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -24.617% |
| Mesoblast Limited | 55.85 Million USD | 97.931% |
| Marizyme, Inc. | 18.56 Million USD | 93.778% |
| Genus plc | 190.6 Million USD | 99.394% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 48.322% |
| Pharming Group N.V. | 109.8 Million USD | 98.948% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -34.315% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 4.816% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -69.916% |
| ContraFect Corporation | -6.02 Million USD | 119.174% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -758.168% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 7.67 Million USD | 84.937% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 78.999% |
| MultiCell Technologies, Inc. | 90.04 USD | -1283139.671% |
| ONE Bio Corp. | 9.04 Million USD | 87.219% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 257.42% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 91.075% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 15.537% |
| Q BioMed Inc. | 4.06 Million USD | 71.541% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.218% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -14.658% |
| Biomind Labs Inc. | 711.4 Thousand USD | -62.416% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.092% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 42.211% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 90.978% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -221.211% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -726.463% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -5715.82% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 47.528% |
| GB Sciences, Inc. | 1.74 Million USD | 33.874% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 728.675% |
| HST Global, Inc. | 96.79 Thousand USD | -1093.711% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -460.298% |
| Halberd Corporation | 144.72 Thousand USD | -698.384% |
| Enzolytics Inc. | 981.65 Thousand USD | -17.702% |
| Agentix Corp. | 37.63 Thousand USD | -2970.418% |
| Resverlogix Corp. | 6.45 Million USD | 82.089% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 271.661% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.057% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.458% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 83.66% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 57.342% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 113.071% |
| AVAX Technologies, Inc. | -5.9 Million USD | 119.573% |
| Zenith Capital Corp. | 10.06 Thousand USD | -11380.813% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.109% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -476.469% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 51.575% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -602.35% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 6407.615% |
| Kadimastem Ltd | -253.1 Thousand USD | 556.507% |
| Helix BioMedix, Inc. | -2.57 Million USD | 144.958% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 94.301% |
| BioStem Technologies, Inc. | 4.47 Million USD | 74.163% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -474.115% |
| LadRx Corporation | -2.03 Million USD | 156.737% |
| Cell Source, Inc. | 9.23 Million USD | 87.484% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -81.909% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -81.909% |
| NovAccess Global Inc. | 2.17 Million USD | 46.961% |
| Affymax, Inc. | -5.59 Million USD | 120.644% |
| Itoco Inc. | 228.3 Thousand USD | -406.09% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -749.649% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 76.691% |
| Mobile Lads Corp. | 484.23 Thousand USD | -138.611% |
| CytoDyn Inc. | 20.26 Million USD | 94.298% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 178682.535% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 12566.407% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 85.006% |
| SYBLEU INC | 473.71 Thousand USD | -143.909% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 74.076% |
| International Stem Cell Corporation | 2.59 Million USD | 55.389% |
| Bioxytran, Inc. | 1.89 Million USD | 39.153% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1751.263% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 47.021% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 66.353% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 86.491% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -49.549% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 192.434% |
| Neutra Corp. | 52.18 Thousand USD | -2114.017% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 146.421% |
| PureTech Health plc | -167.19 Million USD | 100.691% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 571.781% |
| IXICO plc | -4.44 Million USD | 125.996% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 91.259% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.894% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| Cellectis S.A. | -43.81 Million USD | 102.637% |